{"id":"NCT05022004","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","officialTitle":"Therapeutic Equivalence Study of Generic Brinzolamide 1% Ophthalmic Suspension Compared to Reference Listed Drug Azopt速 (Brinzolamide) Ophthalmic Suspension 1% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-20","primaryCompletion":"2022-12-29","completion":"2023-01-06","firstPosted":"2021-08-26","resultsPosted":"2024-01-18","lastUpdate":"2024-01-18"},"enrollment":599,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Brinzolamide ophthalmic suspension","otherNames":[]},{"type":"DRUG","name":"Azopt速","otherNames":[]}],"arms":[{"label":"BRIN-20-01","type":"EXPERIMENTAL"},{"label":"Azopt速","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.","primaryOutcome":{"measure":"Mean Difference in Intraocular Pressure of Both Eyes Between the Two Treatment Groups","timeFrame":"Baseline, Week 2 & Week 6","effectByArm":[{"arm":"BRIN-20-01","deltaMin":24.92,"sd":2.29},{"arm":"Azopt速","deltaMin":25.06,"sd":2.363}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":40,"countries":["India","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":297},"commonTop":["Dysgeusia","Vision Blurred","Foreign Body Sensation in Eyes","Headache","Conjunctival Hyperemia"]}}